SwissCaRe 2022

Coronary angiography and PCI

SwissRDL, Medical Registries and Data Linkage
Institute of Social and Preventive Medicine (ISPM)
University of Bern

Patient hospital label	Hospital patient identification number	
	Surname	Date of birth dd.mm.yyyy
	First name	Gender ○ f ○ m

Baseline characteristics

cvRF

- ☐ None
- ☐ Arterial hypertension (on treatment)
- ☐ Diabetes requiring medication
- ☐ Dyslipidemia (on statin or LDL-C>2.6mmol/L)
- ☐ Smoking (active)
- ☐ Family history

Patient history

- ☐ None
- ☐ Prior PCI (with or without stents)
- ☐ Prior CABG

LVEF (By laevugram or non-invasive imaging test closest to CA)

- ○ Normal (50-70%)
- ○ Mildly reduced (40-49%)
- ○ Moderately reduced (30-39%)
- ○ Severly reduced (<30%)

Out of hospital cardiac arrest

○ Yes ○ No

Cardiogenic shock

(SBP < 90 mmHg for 30 min or vasopressor to maintain, and lactate > 2 mmol/L)

○ Yes ○ No

Intubated

○ Yes ○ No

Mechanical support device(s)

(in case of either cardiogenic shock or high-risk PCI)

☐ None ☐ Impella ☐ ECMO

Indication

Indication (only one answer)

- ○ Clinical presentation as ACS
- ○ Suspected CAD or suspected progression of known CAD
- ○ Planned valvular heart disease intervention
- ○ Follow-up after HTX
- ○ Heart failure (LVEF < 40%)
- ○ Routine follow-up (e.g. after left main PCI)
- ○ Tachy- or bradyarrhythmia
- ○ Planned vascular surgery
- ○ Planned major surgery

If ACS, please specify (Cardiac arrest patients without STEMI count as NSTEMI)

- ○ Unstable angina pectoris (new or progressive angina pectoris, according to Braunwald definition)
- ○ Non-STEMI
- ○ STEMI

If suspected CAD was indicated, please choose the following

Coronary angiography-preceeding test(s) suggesting CAD (high-pretest likelihood)

- ☐ None
- ☐ Treadmill indicating ischemia
- ☐ CCTA with significant stenoses
- ☐ Stress MRI with ischemia
- ☐ Stress TTE with ischemia
- ☐ TTE with hypokinesia
- ☐ Nuclear test with ischemia

SwissCaRe 2022
Coronary angiography and PCI

SwissRDL, Medical Registries and Data Linkage
Institute of Social and Preventive Medicine (ISPM)
University of Bern

Symptoms if suspected or stable CAD

Dyspnoe
○ Yes ○ No

Angina pectoris
○ Yes **CCS** ○ I ○ II ○ III ○ IV
○ No

Anti-anginal drugs (prior or current, betablocker, Calcium channel blocker, long-acting nitrate, Ivabradine, Ranolazine, Trimetazidine)
○ Yes ○ No

STEMI-related referral times

Date of symptoms onset
dd.mm.yyyy

Time of symptoms onset
hh:mm

Date of hospital entry
dd.mm.yyyy

Time of hospital entry
hh:mm

Date of recanalization
dd.mm.yyyy

Time of recanalization
hh:mm

Non-STEMI-related referral times

Time between first ECG and coronary angiography
○ <24 hours ○ 24-48 hours ○ >48 hours

General procedural characteristics

Date of procedure
dd.mm.yyyy

Access (access through which the PCI was finalized)
○ Femoral (Radial attempt converted to femoral counts as femoral)
○ Radial (Brachial counts as radial)

Dose (round to whole number)

Dose unit
○ mGycm2
○ cGycm2 or uGym2

SwissCaRe 2022
Coronary angiography and PCI

SwissRDL, Medical Registries and Data Linkage
Institute of Social and Preventive Medicine (ISPM)
University of Bern

PCI-specific procedural characteristics

Number of treated lesions (Coronary artery lesion undergoing PCI. If two lesions are covered by two or more overlapping stents, this counts as one lesion)

Number of treated vessels (LM, LAD, LCX, RCA, graft)

Unprotected left main stenosis treated ○ Yes ○ No

Number of implanted stents

Number of used drug-eluting balloons

Intervention(s) for stent failure
☐ None ☐ Restenosis ☐ Stent thrombosis

CTO procedure
(Chronic occlusion presumably > 3 months, Subacute ACS presentation excluded)
○ None ○ Antegrade ○ Retrograde

Calcium modification
☐ None ☐ Rotablation
☐ Cutting balloon ☐ Lithotripsy
☐ Scoring balloon ☐ Orbital atherectomy

Bifurcation
○ None
○ 1 stent
○ 2 stents

Intracoronary physiology
☐ None ☐ Resting index (iFR/RFR) ☐ FFR

Intracoronary imaging
☐ None ☐ IVUS ☐ OCT

Complication

Major complication
☐ None
☐ Emergency open heart surgery
☐ Clinically overt stroke
☐ Procedural death

Medication

Prescribed discharge medication (in cathlab)
☐ ASA ☐ P2Y12 inhibitor ☐ N/OAC ☐ Statin

If P2Y12 inhibitor, specify
○ Clopidogrel ○ Ticagrelor
○ Prasugrel ○ Other

If Statin therapy, specify
○ Low-intensity
○ High-intensity (Crestor ≥ 20mg, Atorvastatin ≥ 40mg)

If dual antiplatelet therapy, specify duration
○ <1 month
○ 1 month
○ 3 months
○ 6 months
○ 12 months
○ >12 months

If triple antiplatelet therapy, specify duration
○ <1 month
○ 1 month
○ 3 months
○ 6 months